Cumberland Pharmaceuticals Inc.
NASDAQ:CPIXDrug Manufacturers - Specialty & Generic
-$0.06 today
- Market cap
- $98.52M
- Beta
- 0.10
- P/E (TTM)
- -11.5
- EPS (TTM)
- -$0.48
Volume 0.16M
Average 0.97M
CPIX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Cumberland Pharmaceuticals Inc.NASDAQ: CPIX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q1 FY2026 stock-based compensation of $106.84K rose 44.0% year over year, behind the +48.3% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 37.9% from the prior quarter. Over 3 fiscal years it compounded at -3.0% a year.
Context
- Stock-based compensation amounted to 0.9% of revenue in FY2025, up 0.1 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +44.0% toward the trailing-twelve-month pace of +48.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 408.32K USD
- Year-over-year change
- +35.3%
- 4-year CAGR
- -13.9%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 408.32K | +35.3% |
| FY2024 | 2024-12-31 | 301.9K | -17.3% |
| FY2023 | 2023-12-31 | 365.04K | -18.4% |
| FY2022 | 2022-12-31 | 447.5K | -39.7% |
| FY2021 | 2021-12-31 | 741.87K | — |
Stock-Based Compensation vs competitors
How CPIX compares with its peers on the latest reported figures
- CPIX's LTM Mar 2026 stock-based compensation of $440.95K is the smallest of the 4 companies compared; the peer median is $844.45K.
- Its year-over-year change of +48.3% is the highest of 4, against a peer median of -19.2%.
- Stock-based compensation amounts to 1.1% of revenue for CPIX, versus a peer median of 33.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $10.38M | -11.5% | -13.2% | 39.1% | |
| LTM Mar 2026 | $844.45K | -19.2% | -21.0% | 28.4% | |
| LTM Mar 2026 | $503.13K | -32.6% | -18.2% | — | |
| LTM Mar 2026 | $440.95K | +48.3% | -3.0% | 1.1% | |
| Peer median (excluding CPIX) | $844.45K | -19.2% | -18.2% | 33.7% | |
Competitors are the stored peer set for CPIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (3.6M) | (5.65M) | (6.28M) | (6.48M) | (2.86M) |
| Depreciation & Amortization | 4.61M | 5.33M | 5.77M | 6.04M | 5.29M |
| Deferred Income Tax | (192.82K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 741.87K | 447.5K | 365.04K | 301.9K | 408.32K |
| Change in Working Capital | 8.18M | 10.97M | 4.63M | 1.29M | 2.16M |
| Accounts Receivables | 5.5M | (6.12M) | 3.4M | (1.94M) | (5.24M) |
| Inventory | 4.82M | 1.38M | (23.14K) | 2.41M | 2.24M |
| Accounts Payables | (757.59K) | 15.07M | 3.72M | (991.36K) | 6.71M |
| Other Working Capital | (1.38M) | 644.92K | (2.47M) | 1.82M | (1.55M) |
| Other Non-Cash Items | (3.39M) | (2.64M) | 1.6M | (1.77M) | (59.95K) |
| Operating Cash Flow | 6.34M | 8.45M | 6.09M | (612.19K) | 4.93M |
| Capital Expenditures | (354.46K) | (2.07M) | (453.05K) | (179.71K) | (97.9K) |
| Acquisitions (Net) | 0 | (13.5M) | 0 | 0 | 0 |
| Purchases of Investments | (200K) | 0 | 0 | 0 | (4.48M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 52.57K | 1.9M | 347.36K | 237.56K | (47K) |
| Investing Cash Flow | (501.89K) | (13.67M) | (105.7K) | 57.84K | (4.71M) |
| Debt Repayment | 0 | 1.2M | (3.42M) | 2.49M | (10.04M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 5.27M |
| Common Stock Repurchased | (1.39M) | (1.05M) | (740.53K) | (579.05K) | (263.48K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.17M) | (2.21M) | (3.27M) | (1.72M) | (1.71M) |
| Financing Cash Flow | (3.55M) | (2.06M) | (7.42M) | 196.9K | (6.75M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 2.29M | (7.28M) | (1.44M) | (357.44K) | (6.52M) |
| Free Cash Flow | 5.99M | 6.38M | 5.64M | (791.9K) | 4.83M |
Cumberland Pharmaceuticals Inc.
NASDAQ:CPIX
Intrinsic Alpha fair value
Locked
Current Price
$6.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.